lead by example, overcome difficulties, open up and innovate
Release time:
2022-03-22
Looking back on the years of working in the municipal pharmaceutical company, my achievements cannot be separated from the training and support of the leaders of the group and the pharmaceutical industry, and cannot be separated from the strong support and cooperation of all colleagues. In recent years, municipal pharmaceutical companies have faced unfavorable factors of national policies and a fiercely competitive market, especially with the full implementation of the two-invoice system for drug sales in public hospitals and the rapid advancement of national and local centralized procurement, drug profit margins have been compressed., The distribution of drugs has been in a state of meager profit. In order to optimize personnel and save sales costs, drug sales channels have also become centralized, and drug distribution has been concentrated on commercial distribution companies covering the whole province. The city's pharmaceutical companies are facing competition from Zhejiang provincial-level commercial enterprises in terms of low prices, concessions, market grabbing and homogenization. As the person in charge of an enterprise, I have the responsibility to work with the team to lead a company with more than 100 employees and a history of 70 to overcome difficulties.
After careful market analysis, since the distribution of two-ticket products cannot compete with the distribution enterprises covered by the whole province, our way out lies in the distribution of non-two-ticket products. The goal is clear. On the one hand, we use the group's financial advantages to ensure the sales of existing products by improving services. On the other hand, we have targeted to expand the sales of non-two-vote products, especially special drugs, narcotic drugs, psychotropic drugs and Chinese herbal medicine decoction pieces, as well as OTC products. In addition, we have won their support through frequent market operation and repeated communication with relevant government departments, so that the pharmaceutical company continues to be the only municipal enterprise with special drug distribution qualification in Jinhua City, forming an effective industry barrier. At the same time, we have strengthened close contact with special drug suppliers, made every effort to provide good services, and actively cooperated with them in price maintenance, which not only ensured the interests of suppliers but also ensured the reasonable profits of our company. As the distribution profit margin of special drugs is much higher than that of ordinary drugs, the sharp increase in sales effectively makes up for the decline in sales of two-vote products.
While doing a good job in the sales increase of special drugs, we have vigorously expanded the sales of Chinese herbal pieces and improved our business with Tianshili Group. In 2021 , Health Technology Company processed Chinese herbal pieces to 1100 , bringing the sales of Chinese herbal pieces to a new level. In terms of increasing the sales of OTC , we have introduced the general distributors of well-known brands such as Donge Ejiao and Nanjing Tongrentang in Jinhua area, which not only expanded the sales, but also enhanced the company's influence in Jinhua area.
In order to seek the development of the company, the group purchased a plot of land in Jinxing South Street in the urban area to serve as a reserve for the relocation of the Huancheng East Road warehouse, which did not produce benefits. Through proper renovation, we have successfully hired more than 4 million rents since 2018 . 2021 At the beginning of the year, the plot was included in the government purchasing and storage plan of Jinhua Economic Development Zone. In order to obtain more land compensation, we have taken the initiative to connect with government departments such as development zones, natural resources and planning bureaus for many times, and at the same time compare the compensation levels of other depositors horizontally. Through efforts to coordinate and strive for it, we should also thank the general manager of the pharmaceutical industry for his strong support and realize the maximization of land compensation.
As secretary of the general party branch of the municipal pharmaceutical company, I set an example and distinguish between public and private. Insist on demanding yourself with high standards, take the lead in problems and face up to difficulties. All our party members can also play an exemplary role, making party members the backbone of the company. The general party branch of the pharmaceutical company has also won the title of "Advanced Party Organization " for many years. Under the vanguard and exemplary role of all party members, the cohesion of all employees has been greatly improved, which provides a strong guarantee for the sustainable and stable development of pharmaceutical companies.
In the new year, although the situation in the pharmaceutical industry is more severe, I will live up to my trust and lead all employees to overcome difficulties, pioneer and innovate, and strive for new victories. (According to Wu Weisheng's speech at the summary and commendation meeting of the pharmaceutical company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page